Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANF-Rho in Chronic Neutropenia
NCT02533362Phase 2Withdrawn
- Sponsor
- Prolong Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of ANF-RHO in neutropenia, sponsored by Prolong Pharmaceuticals. Planned start Oct 2015; status: withdrawn.
02
Drugs
ANF-RHO
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02533362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533362.